Monographie - Irinotecan - Stabilis 4.0

Viimeisin päivitys :
19/11/2024

syöpälääke

Irinotecan

Injektioneste

Stabilius liuoksessa

Stabilius seoksissa

Tekijät, jotka vaikuttavat stabiliuteen

Yhteensopivuus

Antotapa

Viitteet

pdf

Kemiallinen rakenne

Kauppanimi

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Asinib	Meksiko
Axinotecan	Saksa
Campto	Belgia, Espanja, Etelä-Afrikka, Hollanti, Intia, Iran, Irlanti, Iso-Britannia, Italia, Itävalta, Japani, Kreikka, Kroatia, Luxemburg, Malesia, Marokko, Norja, Portugali, Puola, Ranska, Ruotsi, Suomi, Sveitsi, Tanska, Thaimaa, Tunisia, Turkki, Unkari, Yhdistyneet arabiemiirikunnat
Camptosar	Brasilia, Kanada, Yhdysvallat
Irinoliquid	Itävalta
Irnocam	Brasilia

Viitteet

Injektioneste

Viitteet : Irinotecan

	tyyppi	julkaisu
1423	Lehti	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1617	Lehti	Li WY, Koda RT. Stability of irinotecan hydrochloride in aqueous solutions. Am J Health-Syst Pharm 2002 ; 59: 539-544.
1662	Lehti	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1918	Lehti	Dodds HM, Craik DJ, Rivory LP. Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition. J Pharm Sci 1997 ; 86, 12: 1410-1416.
1920	Lehti	Akimoto K, Kaway A, Ohya K et al. Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution. Drug Stability 1996 ; 1: 118-122.
1921	Lehti	Akimoto K, Kawai A, Ohya K. Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution. Drug Stability 1996 ; 1; 141-146.
1953	Lehti	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976	Lehti	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.
2027	Lehti	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2143	Lehti	Dodds HM, Robert J, Rivory LP. The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. J Pharm Biomed Anal 1998 ; 17: 785-792.
2168	Lehti	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2241	Lehti	Thiesen J, Krämer I. Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags. J Oncol Pharm Practice 2000 ; 6, 3: 115-121.
2340	Lehti	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
2671	Lehti	Kaiser J, Thiesen J, Krämer I. Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization. J Oncol Pharm Practice 2010 ; 16: 53-61.
3129	Laboratorio	Irinotécan (Campto®) – Résumé des caractéristiques du produits Pfizer 2008
3369	Laboratorio	Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011
3670	Lehti	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3873	Lehti	Tan X, Hu J. Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 2016 ; 73:755.

Mentions Légales